/PRNewswire/ Hearst Health, in partnership with the UCLA Center for SMART Health, today announced that the judges for the 2023 Hearst Health Prize will be.
New approach combines molecular and medical imaging data to diagnose cancer type
Despite our remarkable advances in medicine and healthcare, the cure to cancer continues to elude us. On the bright side, we have made considerable progress in detecting several cancers in earlier stages, allowing doctors to provide treatments that increase long-term survival.
The credit for this is due to integrated diagnosis, an approach to patient care that combines molecular information and medical imaging data to diagnose the cancer type and, eventually, predict treatment outcomes.
There are, however, several intricacies involved. The correlation of molecular patterns, such as gene expression and mutation, with image features (e.g., how a tumor appears in a CT scan), is commonly referred to as radiogenomics. This field is limited by its frequent use of high-dimensional data, wherein the number of features exceeds that of observations.
Study: Radioactive bone cement is a safer alternative for treating bone tumors
A radioactive bone cement that s injected into bone to provide support and local irradiation is proving to be a safer alternative to conventional radiation therapy for bone tumors, according to a study led by University of California, Irvine researchers.
The study shows that this brachytherapy cement can be placed into spinal bones to directly irradiate tumors without harming the spinal cord, and the radioactive material will stay localized in the bones, which promises to virtually eliminate side effects.
Lead researcher Joyce Keyak, UCI professor of radiological sciences, presented the results at the 2021 annual meeting of the Orthopaedic Research Society, which was held virtually Feb. 12-16.